CN1894213A - 取代的四氢咔唑和环戊烷并吲哚衍生物 - Google Patents

取代的四氢咔唑和环戊烷并吲哚衍生物 Download PDF

Info

Publication number
CN1894213A
CN1894213A CNA2004800372808A CN200480037280A CN1894213A CN 1894213 A CN1894213 A CN 1894213A CN A2004800372808 A CNA2004800372808 A CN A2004800372808A CN 200480037280 A CN200480037280 A CN 200480037280A CN 1894213 A CN1894213 A CN 1894213A
Authority
CN
China
Prior art keywords
methylsulfonyl
fluoro
compound
ethyl
carbazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800372808A
Other languages
English (en)
Chinese (zh)
Inventor
C·博里尤
D·格伊
王召印
R·扎姆博尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1894213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CN1894213A publication Critical patent/CN1894213A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CNA2004800372808A 2003-12-15 2004-12-13 取代的四氢咔唑和环戊烷并吲哚衍生物 Pending CN1894213A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53029803P 2003-12-15 2003-12-15
US60/530,298 2003-12-15

Publications (1)

Publication Number Publication Date
CN1894213A true CN1894213A (zh) 2007-01-10

Family

ID=34676897

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800372808A Pending CN1894213A (zh) 2003-12-15 2004-12-13 取代的四氢咔唑和环戊烷并吲哚衍生物

Country Status (7)

Country Link
US (1) US7019022B2 (enExample)
EP (1) EP1697322A4 (enExample)
JP (1) JP2007514005A (enExample)
CN (1) CN1894213A (enExample)
AU (1) AU2004296910A1 (enExample)
CA (1) CA2548602A1 (enExample)
WO (1) WO2005056527A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791689A (zh) * 2010-03-22 2012-11-21 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
CN102026973B (zh) * 2008-05-14 2013-07-10 方济各安吉利克化学联合股份有限公司 3-氨基咔唑化合物、含有它的药物组合物及其制备方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
AU2006214018A1 (en) * 2005-02-17 2006-08-24 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7956082B2 (en) 2005-07-22 2011-06-07 Shionogi & Co., Ltd Indole derivative having PGD2 receptor antagonist activity
EP1932839A4 (en) 2005-09-06 2014-09-10 Shionogi & Co INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
EP2114154B1 (en) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CA2713139C (en) 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA98839C2 (en) * 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2257536A4 (en) * 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2245022A4 (en) * 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
BRPI0912394A2 (pt) 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
AU2009249600A1 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics Holding S.A. Niacin and NSAID for combination therapy
CA2729292C (en) 2008-07-03 2013-09-03 Amira Pharmaceuticals, Inc. Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010057118A2 (en) * 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
JP2013516475A (ja) 2010-01-06 2013-05-13 アミラ ファーマシューティカルズ，インク． Ｄｐ２アンタゴニストおよびその使用
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
CA2939892C (en) 2014-03-17 2020-03-31 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
CN106032383B (zh) * 2015-03-19 2019-08-13 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
CN112362781A (zh) * 2020-11-09 2021-02-12 河北诚信集团有限公司 一种甲基亚磺酸钠的含量测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
IL81325A (en) * 1986-01-23 1990-11-29 Merck Frosst Canada Inc Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them
CA1299577C (en) * 1987-01-09 1992-04-28 John W. Gillard Tetrahydrocarbazole 1-alkanoic acids
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1631547A1 (en) 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
DE602004026597D1 (de) 2003-08-07 2010-05-27 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026973B (zh) * 2008-05-14 2013-07-10 方济各安吉利克化学联合股份有限公司 3-氨基咔唑化合物、含有它的药物组合物及其制备方法
CN102791689A (zh) * 2010-03-22 2012-11-21 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
CN102791689B (zh) * 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途

Also Published As

Publication number Publication date
EP1697322A1 (en) 2006-09-06
US20050154044A1 (en) 2005-07-14
AU2004296910A1 (en) 2005-06-23
EP1697322A4 (en) 2007-12-26
CA2548602A1 (en) 2005-06-23
JP2007514005A (ja) 2007-05-31
WO2005056527A1 (en) 2005-06-23
US7019022B2 (en) 2006-03-28

Similar Documents

Publication Publication Date Title
CN1902176A (zh) 氟取代的环烷酸吲哚,含这种化合物的组合物和治疗方法
CN1214007C (zh) 环戊二烯并吲哚、含有这类化合物的组合物及治疗方法
US7019022B2 (en) Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN1791577A (zh) 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
AU2003202343A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists
CN1098262C (zh) 光学活性的哌啶化合物的酸加成盐和其制备方法
CN1805959A (zh) 作为dp拮抗剂的环烷吡咯并吡啶
CN1805960A (zh) 7－氮杂吲哚类化合物以及其用作治疗剂的应用
CN1033379A (zh) 羟基嘧啶的酰基衍生物及其制备方法
CN101048392A (zh) 新用途
CN1025191C (zh) 苯并咪唑衍生物的制备方法
HK1096090A (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
CN1087084A (zh) 新的异丁基取代的甲磺酰基-喹啉基甲氧基苯基-环烷基乙酰胺
CN1571665A (zh) 升高丙酮酸脱氢酶活性的被取代的n－苯基2－羟基－2－甲基－3,3,3－三氟丙酰胺衍生物
CN1152915A (zh) 作为白三烯拮抗剂的喹啉衍生物
HK1058934B (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
HK1149931A (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication